Targeted Disruption of Heparan Sulfate Interaction with Hepatocyte and Vascular Endothelial Growth Factors Blocks Normal and Oncogenic Signaling

Cancer Cell

Volumn 22, Issue 2, 2012, Pages 250-262

  Cecchi, Fabiola ^a   Pajalunga, Deborah ^b,c,f   Fowler, C Andrew ^b,g   Üren, Aykut ^d   Rabe, Daniel C ^a   Peruzzi, Benedetta ^a,h   MacDonald, Nicholas J ^c,i   Blackman, Davida K ^c,j   Stahl, Stephen J ^e   Byrd, R Andrew ^b   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c ENTREMED INC   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^f Higher Institute of Health   (Italy)

^g UNIVERSITY OF IOWA   (United States)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j ProMetic Life Sciences Inc   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEPARAN SULFATE; NK1 3S PROTEIN; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL INTERACTION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG POTENCY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 84865107470     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.06.029     Document Type: Article

References (51)

1. Appleton B.A., Wu P., Maloney J., Yin J., Liang W.C., Stawicki S., Mortara K., Bowman K.K., Elliott J.M., Desmarais W., et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J. 2007, 26:4902-4912.
2. Backer M.V., Gaynutdinov T.I., Patel V., Bandyopadhyaya A.K., Thirumamagal B.T., Tjarks W., Barth R.F., Claffey K., Backer J.M. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther. 2005, 4:1423-1429.
3. Boccaccio C., Comoglio P.M. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 2006, 6:637-645.
4. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V.V., Stalmans I., Mattot V., et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 1999, 5:495-502.
5. Castagnino P., Lorenzi M.V., Yeh J., Breckenridge D., Sakata H., Munz B., Werner S., Bottaro D.P. Neu differentiation factor/heregulin induction by hepatocyte and keratinocyte growth factors. Oncogene 2000, 19:640-648.
6. Cecchi F., Rabe D.C., Bottaro D.P. Targeting the HGF/Met signalling pathway in cancer. Eur. J. Cancer 2010, 46:1260-1270.
7. Chirgadze D.Y., Hepple J.P., Zhou H., Byrd R.A., Blundell T.L., Gherardi E. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat. Struct. Biol. 1999, 6:72-79.
8. Christinger H.W., Fuh G., de Vos A.M., Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J. Biol. Chem. 2004, 279:10382-10388.
9. Dougher A.M., Wasserstrom H., Torley L., Shridaran L., Westdock P., Hileman R.E., Fromm J.R., Anderberg R., Lyman S., Linhardt R.J., et al. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors 1997, 14:257-268.
10. Favier B., Alam A., Barron P., Bonnin J., Laboudie P., Fons P., Mandron M., Herault J.P., Neufeld G., Savi P., et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006, 108:1243-1250.
11. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
12. Fuh G., Li B., Crowley C., Cunningham B., Wells J.A. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 1998, 273:11197-11204.
13. Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
14. Gerber H.P., Wu X., Yu L., Wiesmann C., Liang X.H., Lee C.V., Fuh G., Olsson C., Damico L., Xie D., et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. USA 2007, 104:3478-3483.
15. Gherardi E., Sandin S., Petoukhov M.V., Finch J., Youles M.E., Ofverstedt L.G., Miguel R.N., Blundell T.L., Vande Woude G.F., Skoglund U., Svergun D.I. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl. Acad. Sci. USA 2006, 103:4046-4051.
16. Gluzman-Poltorak Z., Cohen T., Herzog Y., Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]. J. Biol. Chem. 2000, 275:18040-18045.
17. Hartmann G., Prospero T., Brinkmann V., Ozcelik C., Winter G., Hepple J., Batley S., Bladt F., Sachs M., Birchmeier C., et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 1998, 8:125-134.
18. Kinosaki M., Yamaguchi K., Murakami A., Ueda M., Morinaga T., Higashio K. Identification of heparin-binding stretches of a naturally occurring deleted variant of hepatocyte growth factor (dHGF). Biochim. Biophys. Acta 1998, 1384:93-102.
19. Krilleke D., DeErkenez A., Schubert W., Giri I., Robinson G.S., Ng Y.S., Shima D.T. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. J. Biol. Chem. 2007, 282:28045-28056.
20. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
21. Lietha D., Chirgadze D.Y., Mulloy B., Blundell T.L., Gherardi E. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 2001, 20:5543-5555.
22. Lokker N.A., Presta L.G., Godowski P.J. Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. Protein Eng. 1994, 7:895-903.
23. Lyon M., Deakin J.A., Gallagher J.T. The mode of action of heparan and dermatan sulfates in the regulation of hepatocyte growth factor/scatter factor. J. Biol. Chem. 2002, 277:1040-1046.
24. Lyon M., Deakin J.A., Lietha D., Gherardi E., Gallagher J.T. The interactions of hepatocyte growth factor/scatter factor and its NK1 and NK2 variants with glycosaminoglycans using a modified gel mobility shift assay. Elucidation of the minimal size of binding and activatory oligosaccharides. J. Biol. Chem. 2004, 279:43560-43567.
25. Matsumoto K., Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J. Biochem. 1996, 119:591-600.
26. Michalopoulos G.K. Liver regeneration. J. Cell. Physiol. 2007, 213:286-300.
27. Mizuno K., Inoue H., Hagiya M., Shimizu S., Nose T., Shimohigashi Y., Nakamura T. Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor. J. Biol. Chem. 1994, 269:1131-1136.
28. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005, 16:107-137.
29. Okigaki M., Komada M., Uehara Y., Miyazawa K., Kitamura N. Functional characterization of human hepatocyte growth factor mutants obtained by deletion of structural domains. Biochemistry 1992, 31:9555-9561.
30. Orian-Rousseau V., Chen L., Sleeman J.P., Herrlich P., Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16:3074-3086.
31. Parker M.W., Xu P., Li X., Vander Kooi C.W. Structural basis for the selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. J. Biol. Chem. 2012, 2012:7.
32. Peschard P., Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene 2007, 26:1276-1285.
33. Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 2001, 114:853-865.
34. Rubin J.S., Day R.M., Breckenridge D., Atabey N., Taylor W.G., Stahl S.J., Wingfield P.T., Kaufman J.D., Schwall R., Bottaro D.P. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling. J. Biol. Chem. 2001, 276:32977-32983.
35. Sakata H., Stahl S.J., Taylor W.G., Rosenberg J.M., Sakaguchi K., Wingfield P.T., Rubin J.S. Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling. J. Biol. Chem. 1997, 272:9457-9463.
36. Sarrazin S., Lamanna W.C., Esko J.D. Heparan sulfate proteoglycans. Cold Spring Harb. Perspect. Biol. 2011, 3:1-33.
37. Schwall R.H., Chang L.Y., Godowski P.J., Kahn D.W., Hillan K.J., Bauer K.D., Zioncheck T.F. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J. Cell Biol. 1996, 133:709-718.
38. Shintani Y., Takashima S., Asano Y., Kato H., Liao Y., Yamazaki S., Tsukamoto O., Seguchi O., Yamamoto H., Fukushima T., et al. Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. EMBO J. 2006, 25:3045-3055.
39. Stahl S.J., Wingfield P.T., Kaufman J.D., Pannell L.K., Cioce V., Sakata H., Taylor W.G., Rubin J.S., Bottaro D.P. Functional and biophysical characterization of recombinant human hepatocyte growth factor isoforms produced in Escherichia coli. Biochem. J. 1997, 326:763-772.
40. Stamos J., Lazarus R.A., Yao X., Kirchhofer D., Wiesmann C. Crystal structure of the HGF β-chain in complex with the Sema domain of the Met receptor. EMBO J. 2004, 23:2325-2335.
41. Tao Q., Backer M.V., Backer J.M., Terman B.I. Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling. J. Biol. Chem. 2001, 276:21916-21923.
42. Tolbert W.D., Daugherty J., Gao C., Xie Q., Miranti C., Gherardi E., Woude G.V., Xu H.E. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc. Natl. Acad. Sci. USA 2007, 104:14592-14597.
43. Ultsch M., Lokker N.A., Godowski P.J., de Vos A.M. Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution. Structure 1998, 6:1383-1393.
44. van der Voort R., Taher T.E., Wielenga V.J., Spaargaren M., Prevo R., Smit L., David G., Hartmann G., Gherardi E., Pals S.T. Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J. Biol. Chem. 1999, 274:6499-6506.
45. Wielenga V.J., van der Voort R., Taher T.E., Smit L., Beuling E.A., van Krimpen C., Spaargaren M., Pals S.T. Expression of c-Met and heparan-sulfate proteoglycan forms of CD44 in colorectal cancer. Am. J. Pathol. 2000, 157:1563-1573.
46. Wijelath E., Namekata M., Murray J., Furuyashiki M., Zhang S., Coan D., Wakao M., Harris R.B., Suda Y., Wang L., Sobel M. Multiple mechanisms for exogenous heparin modulation of vascular endothelial growth factor activity. J. Cell. Biochem. 2010, 111:461-468.
47. Yang Y., Xie P., Opatowsky Y., Schlessinger J. Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling. Proc. Natl. Acad. Sci. USA 2010, 107:1906-1911.
48. Youles M., Holmes O., Petoukhov M.V., Nessen M.A., Stivala S., Svergun D.I., Gherardi E. Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J. Mol. Biol. 2008, 377:616-622.
49. Zhou H., Mazzulla M.J., Kaufman J.D., Stahl S.J., Wingfield P.T., Rubin J.S., Bottaro D.P., Byrd R.A. The solution structure of the N-terminal domain of hepatocyte growth factor reveals a potential heparin-binding site. Structure 1998, 6:109-116.
50. Zhou H., Casas-Finet J.R., Heath Coats R., Kaufman J.D., Stahl S.J., Wingfield P.T., Rubin J.S., Bottaro D.P., Byrd R.A. Identification and dynamics of a heparin-binding site in hepatocyte growth factor. Biochemistry 1999, 38:14793-14802.
51. Zioncheck T.F., Richardson L., Liu J., Chang L., King K.L., Bennett G.L., Fügedi P., Chamow S.M., Schwall R.H., Stack R.J. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J. Biol. Chem. 1995, 270:16871-16878.